Novartis scraps key PD-1 submission, while touting 'significant bolt-on M&A firepower'

Nicole DeFeudis

Editor

Novartis is no longer submitting tislelizumab for approval in the US as a monotherapy for non-small cell lung cancer — marking the second major setback in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis scraps key PD-1 submission, while touting 'significant bolt-on M&A firepower'

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Regeneron forges ahead in factor XI despite field’s mixed results

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

FDA rejects Zealand Pharma's short bowel syndrome drug

No­var­tis scraps key PD-1 sub­mis­sion, while tout­ing 'sig­nif­i­cant bolt-on M&A fire­pow­er'

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

Novartis scraps key PD-1 submission, while touting 'significant bolt-on M&A firepower'

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Regeneron forges ahead in factor XI despite field’s mixed results

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

FDA rejects Zealand Pharma's short bowel syndrome drug